查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1590884

H1N1 疫苗市场：按给药途径、品牌类型和分销管道划分 - 2025-2030 年全球预测

H1N1 Vaccines Market by Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines), Type of Brand (Agripal, Fiuarix, Influgen), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年H1N1疫苗市值为99.3亿美元，预计2024年将达到134.5亿美元，复合年增长率为35.51%，2030年将达到833.9亿美元。

H1N1 疫苗市场的范围和定义围绕着对抗 H1N1 流感病毒（俗称猪流感）的疫苗的开发、生产和分销。这些疫苗的需求源自于流感大流行造成的全球健康风险，流感大流行导致广泛的疾病和死亡。主要用途包括对高风险族群进行免疫接种，例如医护人员、儿童、老年人和免疫力较弱的人。最终用途广泛，包括公共卫生活动、医院和临床环境以及政府储存策略。市场成长的推动因素包括感染疾病预防意识的增强、疫苗技术的进步以及政府卫生政策的支持。最近的市场趋势凸显了新兴市场的扩张潜力，利用mRNA技术快速开拓疫苗，以及加强低温运输物流以确保疫苗的稳定性和到达偏远地区都强调有机会。抓住这些机会的研究包括投资下一代疫苗的先进研究和开发（R&D）、建立广泛的分销网络的战略伙伴关係以及加强卫生基础设施的公私伙伴关係，其中包括参与合作。

主要市场统计
基准年[2023] 99.3亿美元
预测年份 [2024] 134.5亿美元
预测年份 [2030] 833.9亿美元
复合年增长率（%） 35.51%

然而，限制因素包括推迟疫苗核准的监管障碍、全球分配中的政治和后勤挑战，以及公众对疫苗的犹豫不决以及错误讯息的加剧。应对这些挑战需要持续的教育工作以及关于疫苗安全性和有效性的透明沟通。最具创新潜力的领域包括开发通用流感疫苗、加强疫苗储存和输送系统，以及整合数位卫生技术以更好地追踪和管理疫苗分发。对这个市场性质的考察表明，在应对紧急公共卫生需求和预测未来疫情爆发的双重迫切需求的推动下，该市场竞争激烈且发展迅速。成功进入这个市场需要战略远见和敏捷性，以应对疫苗市场特有的复杂性。

市场动态：揭示快速发展的 H1N1 疫苗市场的关键市场洞察

H1N1 疫苗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 新增流感感染人数增加
    • 孕妇和儿童对灭活流感疫苗的需求
    • 转向基于细胞的製造
  • 市场限制因素
    • 製造过程耗时且昂贵
  • 市场机会
    • 官民合作关係实现具有成本效益的供应
    • 疫苗技术进步
  • 市场挑战
    • H1N1 疫苗的常见副作用

波特五力：驾驭 H1N1 疫苗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 H1N1 疫苗市场的外部影响

外部宏观环境因素对甲型H1N1疫苗市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解甲型H1N1流感疫苗市场竞争状况

对 H1N1 疫苗市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 H1N1 疫苗市场供应商绩效评估

FPNV定位矩阵是评估H1N1疫苗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议描绘 H1N1 疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，H1N1 疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 流行性 H1N1 流感感染疾病发生率上升
      • 孕妇和儿童对灭活流感疫苗的需求
      • 过渡到基于细胞的製造
    • 抑制因素
      • 製造过程耗时且成本高
    • 机会
      • 官民合作关係实现具有成本效益的供应
      • 疫苗技术进步
    • 任务
      • H1N1 疫苗的常见副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 H1N1 疫苗市场：依给药途径

  • 皮内疫苗
  • 肌内疫苗
  • 鼻内疫苗

第七章 H1N1 疫苗品牌市场

  • 阿格里帕尔
  • 费里克斯
  • 流感
  • 流感回来
  • 纳索瓦茨
  • 瓦克西握把

第八章 H1N1 疫苗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第九章 美洲H1N1疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章 亚太地区H1N1疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲H1N1疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Baxter International Inc.
  • Cipla Limited
  • Cochin Shipyard Ltd.
  • Glaxo Smith Kline
  • Hualan Biological Engineering Inc.
  • MedImmune, LLC
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer Inc.
  • Sanofi SA
  • Sinovac Biotech Ltd.
Product Code: MRR-437E9896A50B

The H1N1 Vaccines Market was valued at USD 9.93 billion in 2023, expected to reach USD 13.45 billion in 2024, and is projected to grow at a CAGR of 35.51%, to USD 83.39 billion by 2030.

The H1N1 vaccine market scope and definition revolve around the development, production, and distribution of vaccines aimed at combating the H1N1 influenza virus, commonly known as swine flu. The necessity for these vaccines stems from the global health risk presented by flu outbreaks, which can lead to widespread illness and mortality. Applications primarily include immunization efforts targeting high-risk populations such as healthcare workers, children, the elderly, and those with compromised immune systems. End-use scope spans public health initiatives, hospital and clinical settings, and government stockpiling strategies. Market growth is driven by factors such as increasing awareness of infectious disease prevention, advancements in vaccine technology, and supportive governmental health policies. Recent market dynamics highlight potential opportunities in the expansion within emerging markets, leveraging mRNA technology for rapid vaccine development, and enhancing cold chain logistics to ensure vaccine stability and reach in remote areas. Recommendations to seize these opportunities include investing in advanced research and development (R&D) for next-generation vaccines, forging strategic partnerships for broad distribution networks, and engaging in public-private collaborations to enhance health infrastructure.

KEY MARKET STATISTICS
Base Year [2023] USD 9.93 billion
Estimated Year [2024] USD 13.45 billion
Forecast Year [2030] USD 83.39 billion
CAGR (%) 35.51%

However, limitations include regulatory hurdles that can delay vaccine approval, political and logistical challenges in global distribution, and public vaccine hesitancy amplified by misinformation. Addressing these challenges calls for continuous education efforts and transparent communication about vaccine safety and efficacy. The best possible areas of innovation involve developing universal flu vaccines, enhancing vaccine storage and delivery systems, and integrating digital health technologies for better tracking and managing vaccine distribution. Insight into the nature of this market reveals it to be highly competitive and rapidly evolving, driven by the dual imperatives of addressing immediate public health needs and anticipating future outbreaks. Successful engagement requires strategic foresight and agility to navigate the complexities inherent in the vaccine landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving H1N1 Vaccines Market

The H1N1 Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of epidemic H1N1 infection
    • Demand for inactivated influenza vaccine in pregnant women and children
    • Shift towards cell-based manufacturing
  • Market Restraints
    • Time consuming manufacturing process and high cost
  • Market Opportunities
    • Public-private partnerships for cost effective supply
    • Technological advancements in the vaccines
  • Market Challenges
    • Common side effects associated with H1N1 vaccines

Porter's Five Forces: A Strategic Tool for Navigating the H1N1 Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the H1N1 Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the H1N1 Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the H1N1 Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the H1N1 Vaccines Market

A detailed market share analysis in the H1N1 Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the H1N1 Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the H1N1 Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the H1N1 Vaccines Market

A strategic analysis of the H1N1 Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the H1N1 Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Baxter International Inc., Cipla Limited, Cochin Shipyard Ltd., Glaxo Smith Kline, Hualan Biological Engineering Inc., MedImmune, LLC, Merck KGaA, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Sanofi S.A., and Sinovac Biotech Ltd..

Market Segmentation & Coverage

This research report categorizes the H1N1 Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Intradermal Vaccines, Intramuscular Vaccines, and Intranasal Vaccines.
  • Based on Type of Brand, market is studied across Agripal, Fiuarix, Influgen, Influvac, Nasovac, and Vaxigrip.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of epidemic H1N1 infection
      • 5.1.1.2. Demand for inactivated influenza vaccine in pregnant women and children
      • 5.1.1.3. Shift towards cell-based manufacturing
    • 5.1.2. Restraints
      • 5.1.2.1. Time consuming manufacturing process and high cost
    • 5.1.3. Opportunities
      • 5.1.3.1. Public-private partnerships for cost effective supply
      • 5.1.3.2. Technological advancements in the vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Common side effects associated with H1N1 vaccines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. H1N1 Vaccines Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Intradermal Vaccines
  • 6.3. Intramuscular Vaccines
  • 6.4. Intranasal Vaccines

7. H1N1 Vaccines Market, by Type of Brand

  • 7.1. Introduction
  • 7.2. Agripal
  • 7.3. Fiuarix
  • 7.4. Influgen
  • 7.5. Influvac
  • 7.6. Nasovac
  • 7.7. Vaxigrip

8. H1N1 Vaccines Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Americas H1N1 Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific H1N1 Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa H1N1 Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Baxter International Inc.
  • 3. Cipla Limited
  • 4. Cochin Shipyard Ltd.
  • 5. Glaxo Smith Kline
  • 6. Hualan Biological Engineering Inc.
  • 7. MedImmune, LLC
  • 8. Merck KGaA
  • 9. Mitsubishi Tanabe Pharma Corporation
  • 10. Pfizer Inc.
  • 11. Sanofi S.A.
  • 12. Sinovac Biotech Ltd.

LIST OF FIGURES

  • FIGURE 1. H1N1 VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. H1N1 VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL H1N1 VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES H1N1 VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES H1N1 VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. H1N1 VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. H1N1 VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. H1N1 VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL H1N1 VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. H1N1 VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL H1N1 VACCINES MARKET SIZE, BY INTRADERMAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL H1N1 VACCINES MARKET SIZE, BY INTRAMUSCULAR VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL H1N1 VACCINES MARKET SIZE, BY INTRANASAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGRIPAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL H1N1 VACCINES MARKET SIZE, BY FIUARIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL H1N1 VACCINES MARKET SIZE, BY INFLUGEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL H1N1 VACCINES MARKET SIZE, BY INFLUVAC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL H1N1 VACCINES MARKET SIZE, BY NASOVAC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL H1N1 VACCINES MARKET SIZE, BY VAXIGRIP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL H1N1 VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL H1N1 VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES H1N1 VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. H1N1 VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. H1N1 VACCINES MARKET, FPNV POSITIONING MATRIX, 2023